The utilization of microbial cell-free DNA next-generation sequencing for the detection of human herpesvirus-8 in a quaternary care center.

IF 3.8 Q2 INFECTIOUS DISEASES

Therapeutic Advances in Infectious Disease Pub Date : 2025-01-23 eCollection Date: 2025-01-01 DOI:10.1177/20499361251313832

Rebecca Berger, Jennifer Jacobe, Fernando H Centeno, Todd Lasco, Mayar Al Mohajer

{"title":"The utilization of microbial cell-free DNA next-generation sequencing for the detection of human herpesvirus-8 in a quaternary care center.","authors":"Rebecca Berger, Jennifer Jacobe, Fernando H Centeno, Todd Lasco, Mayar Al Mohajer","doi":"10.1177/20499361251313832","DOIUrl":null,"url":null,"abstract":"Background: Human herpesvirus-8 (HHV8) can present with cutaneous or extracutaneous manifestations. While violaceous skin lesions characterize cutaneous Kaposi sarcoma, extracutaneous HHV8 is challenging to diagnose due to nonspecific symptoms.Objectives: We evaluated the role of microbial cell-free DNA next-generation sequencing (mcfDNA NGS) in diagnosing HHV8-related illness.Design: Retrospective analysis.Methods: Between 2017 and 2024, we reviewed the medical charts of 10 immunosuppressed patients at a quaternary care center who had positive HHV8 mcfDNA NGS results.Results: The clinical and laboratory turnaround times of mcfDNA NGS were 3 and 1 days, respectively (8.5 and 7 days for immunohistochemistry vs 5.5 and 2 days for serum HHV8 polymerase chain reaction). Eight patients received HHV8-related diagnoses, while two had unrelated conditions. Management changed in six patients post-testing due to outpatient specialist referral or adjusting antimicrobials.Conclusion: mcfDNA NGS can aid clinicians in identifying HHV8-related diseases before tissue sampling and adjusting treatment plans in patients with nonspecific disease manifestations.","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251313832"},"PeriodicalIF":3.8000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758512/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Infectious Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20499361251313832","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Human herpesvirus-8 (HHV8) can present with cutaneous or extracutaneous manifestations. While violaceous skin lesions characterize cutaneous Kaposi sarcoma, extracutaneous HHV8 is challenging to diagnose due to nonspecific symptoms.

Objectives: We evaluated the role of microbial cell-free DNA next-generation sequencing (mcfDNA NGS) in diagnosing HHV8-related illness.

Design: Retrospective analysis.

Methods: Between 2017 and 2024, we reviewed the medical charts of 10 immunosuppressed patients at a quaternary care center who had positive HHV8 mcfDNA NGS results.

Results: The clinical and laboratory turnaround times of mcfDNA NGS were 3 and 1 days, respectively (8.5 and 7 days for immunohistochemistry vs 5.5 and 2 days for serum HHV8 polymerase chain reaction). Eight patients received HHV8-related diagnoses, while two had unrelated conditions. Management changed in six patients post-testing due to outpatient specialist referral or adjusting antimicrobials.

Conclusion: mcfDNA NGS can aid clinicians in identifying HHV8-related diseases before tissue sampling and adjusting treatment plans in patients with nonspecific disease manifestations.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊